Peter Huntsman, CEO of the Huntsman Foundation and chairman and CEO of the Huntsman Cancer Foundation (HCF), announced today a transformational $30 million gift from the family’s foundation. This donation allows Huntsman Cancer Institute (HCI) at the University of Utah (U of U) to better plan for and address the future needs of cancer patients in the Mountain West. The gift is in addition to the $40 million already raised by HCF to support the construction of the Kathryn F. Kirk Center for Comprehensive Cancer Care and Women’s Cancers at Huntsman Cancer Institute.
Researchers at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) contributed to the development of a global resource that includes data on thousands of inherited variants in the BRCA1 and BRCA2 genes. This resource, called the BRCA Exchange, is now available to the public. The BRCA Exchange was created through the BRCA Challenge, a long-term demonstration project initiated by the Global Alliance for Genomics and Health (GA4GH) to enhance sharing of BRCA1/BRCA2 data. The new resource will allow clinicians to review expert classifications of variants in these major cancer predisposition genes as part of their individual assessment of cancer prevention, screenings, and interventions for patients at higher risk for breast, ovarian, and certain other cancers.
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has launched a unique new service called Huntsman at Home. This service brings HCI-quality care into the homes of HCI patients, whose medical needs range from symptom management to physical therapy after cancer surgery to end-of-life care. Huntsman at Home may also allow patients to be discharged from the HCI cancer hospital sooner by enabling them to receive follow-up care in their own home.
An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease. The results were published this week in the journal Genetics in Medicine.
Today officials at Huntsman Cancer Institute (HCI) at the University of Utah (U of U) began construction on a project that will house the region’s first proton therapy center and announced the new center will be named in honor of United States Senator Orrin G. Hatch. Cancer patients and loved ones joined leaders from HCI, Huntsman Cancer Foundation (HCF), and the U of U to mark the occasion.
The Pancreatic Cancer Collective, the strategic partnership of the Lustgarten Foundation and Stand Up To Cancer (SU2C), has awarded a total of $7 million in first-round “New Therapies Challenge” grants to seven teams of top cancer researchers to explore new pancreatic cancer treatments, the American Association for Cancer Research, the Scientific Partner of SU2C, announced today. Each team will receive up to $1 million in initial funding, with $4 million per team for clinical studies awaiting the most successful projects in the second round.
An interdisciplinary team of researchers at Huntsman Cancer Institute (HCI) at the University of Utah (the university) was recently awarded a prestigious team science grant through the National Cancer Institute’s (NCI) Cancer Moonshot initiative to study genetic counseling, genetic communication and genetic services to patients. The grant is expected to provide more than $5 million in research project support over the next five years.
Huntsman Cancer Institute (HCI) and the University of Utah (U of U) will receive up to $28 million over the next 10 years from the National Cancer Institute (NCI) to continue its participation in the NCI’s Surveillance Epidemiology and End Results (SEER) program, if all contract options are exercised. The work is conducted through the Utah Cancer Registry (UCR) at the U of U, in collaboration with the Utah Department of Health.
Research at Huntsman Cancer Institute at the University of Utah yielded new insights into the environment surrounding different types of lung tumors, and described how these complex cell ecosystems may in turn ultimately affect response to treatment. The results were published today in Immunity and featured on the print cover of the journal.
- New research published in Nature Communications from scientists at Huntsman Cancer Institute (HCI) at the University of Utah (U of U), in collaboration with the Stanford University School of Medicine, shows a specific protein regulates both the initiation of cancer spreading and the self-renewal of cancer cells in medulloblastoma, a type of pediatric brain cancer.
Huntsman Cancer Institute at the University of Utah, in partnership with Grand Valley Oncology, recently opened a telemedicine clinic to serve blood and marrow transplant patients in Mesa County, Colorado and the surrounding areas. This service will bring cutting-edge care to remote communities without requiring the patient to travel long distances to Salt Lake City for follow-up appointments.
Huntsman Cancer Foundation (HCF) announces that several individuals and business organizations have committed a total of $40 million to support a proposed major building expansion of Huntsman Cancer Institute (HCI) at the University of Utah (U of U).
YWCA Utah has selected Mary Beckerle, PhD, CEO of Huntsman Cancer Institute (HCI) at the University of Utah (U of U) to receive the Outstanding Achievement Award in Medicine and Health. Beckerle will be honored today at the 30th annual YWCA Utah LeaderLuncheon.
Scientists at Huntsman Cancer Institute (HCI) at the University of Utah (U of U), in collaboration with the Salk Institute for Biological Studies, have generated the first single cell resolution atlas of genes that control the formation of breast tissue. The atlas provides a comprehensive molecular map that will be used to help researchers understand how breast cancers form and to pinpoint new ways to prevent, diagnose, and treat the disease.
Huntsman Cancer Institute (HCI) at the University of Utah today announced the appointment of Cornelia Ulrich, PhD, MS, as director of its National Cancer Institute-Designated Comprehensive Cancer Center. She will oversee HCI’s academic consortium of nearly 200 cancer research teams. Ulrich will lead efforts to advance HCI’s research in laboratory, clinical and population science, with the goal of improving cancer prevention and treatment. – Huntsman Cancer Institute (HCI) at the University of Utah today announced the appointment of Cornelia Ulrich, PhD, MS, as director of its National Cancer Institute-Designated Comprehensive Cancer Center. She will oversee HCI’s academic consortium of nearly 200 cancer research teams. Ulrich will lead efforts to advance HCI’s research in laboratory, clinical and population science, with the goal of improving cancer prevention and treatment.
Huntsman Cancer Institute (HCI) physician-scientist Ahmad Halwani, MD, has been selected by the National Cancer Institute (NCI) to receive a Cancer Clinical Investigator Team Leadership Award. This award recognizes physician-scientists for their contributions to clinical cancer research. It also provides financial support for ongoing research and leadership development to enable recipients to further advance their clinical research careers.
Nearly 80 million Americans — one out of every four people — are infected with human papillomavirus (HPV). And of those millions, more than 31,000 will be diagnosed with an HPV-related cancer this year. Despite those staggering figures and the availability of a vaccine to prevent the infections that cause these cancers, HPV vaccination remains low in the United States.
Often what kills cancer patients is not the cancer at its original or primary site, but its spread to secondary sites within the body, through a process called metastasis. In the case of breast cancer, the tumor often spreads to the bone, and it is this bone metastasis that results in intense pain and precedes spread to other organs.
Huntsman Cancer Institute announced today that it has been certified to offer both chimeric antigen receptor (CAR) T cell therapies recently approved by the U.S. Food and Drug Administration. The therapies are approved for types of aggressive blood cancers, including B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. HCI is one of a few locations nationwide, and the only in the Mountain West, approved to offer these new therapies to adult cancer patients.